Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase IV, Non-interventional, Prospective, Open Label, Non Comparative Real Life Data Collection of Depo-Eligard 7.5 mg, 22.5 mg and 45 mg in Male Prostate Cancer Patients

Next Previous
X
Search
Trial Profile

Phase IV, Non-interventional, Prospective, Open Label, Non Comparative Real Life Data Collection of Depo-Eligard 7.5 mg, 22.5 mg and 45 mg in Male Prostate Cancer Patients

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Leuprorelin (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions
  • Acronyms TREMODI
  • Sponsors Astellas Pharma

    • Most Recent Events

    • 10 Jan 2014 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
    • 21 Nov 2013 Planned End Date changed from 1 Oct 2015 to 1 Dec 2013 as reported by ClinicalTrials.gov.
    • 30 Jul 2013 Planned End Date changed from 1 Jan 2015 to 1 Oct 2015 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top